MX342120B - Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin. - Google Patents

Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin.

Info

Publication number
MX342120B
MX342120B MX2013000339A MX2013000339A MX342120B MX 342120 B MX342120 B MX 342120B MX 2013000339 A MX2013000339 A MX 2013000339A MX 2013000339 A MX2013000339 A MX 2013000339A MX 342120 B MX342120 B MX 342120B
Authority
MX
Mexico
Prior art keywords
delivery system
release
immediate
life
delayed release
Prior art date
Application number
MX2013000339A
Other languages
English (en)
Other versions
MX2013000339A (es
Inventor
James Trinca Green
William Owen Wilkison
Original Assignee
William Owen Wilkison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Owen Wilkison filed Critical William Owen Wilkison
Publication of MX2013000339A publication Critical patent/MX2013000339A/es
Publication of MX342120B publication Critical patent/MX342120B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una combinación de sistema de administración de liberación inmediata/prolongada para compuestos que tienen una vida corta media, como el medicamento anti diabético remogliflozin etabonato, se proporciona y que proporciona una forma de dosificación que tiene dos fases características de liberación, una fórmula que promueve la liberación inmediata del compuesto al ser ingerido y otra fórmula que retrasa la liberación del compuesto para que el régimen de dosificación del remogliflozin etabonato una vez al día, pueda ser logrado mientras se proporciona control efectivo de la glucosa en plasma y minimizar la expresión durante la noche al compuesto. El sistema de administración incluye pero no se limita a una combinación de cubierta entérica de una fórmula de liberación inmediata para que se proporcione una liberación prolongada. También se proporcionan, los métodos para formar el sistema de liberación inmediata/prolongada y el uso de dicho sistema de administración para tratar pacientes diabéticos.
MX2013000339A 2010-07-09 2011-07-07 Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin. MX342120B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36294610P 2010-07-09 2010-07-09
PCT/US2011/043143 WO2012006398A2 (en) 2010-07-09 2011-07-07 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin

Publications (2)

Publication Number Publication Date
MX2013000339A MX2013000339A (es) 2015-05-11
MX342120B true MX342120B (es) 2016-09-14

Family

ID=45441790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000339A MX342120B (es) 2010-07-09 2011-07-07 Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin.

Country Status (16)

Country Link
US (1) US10940159B2 (es)
EP (1) EP2590634B1 (es)
JP (2) JP6042330B2 (es)
KR (1) KR101942590B1 (es)
CN (2) CN103153288B (es)
AU (1) AU2011276254B2 (es)
BR (1) BR112013000626B1 (es)
CA (1) CA2804926C (es)
ES (1) ES2575860T3 (es)
IL (1) IL224142B (es)
MX (1) MX342120B (es)
MY (1) MY161846A (es)
PL (1) PL2590634T3 (es)
RU (2) RU2596787C2 (es)
WO (1) WO2012006398A2 (es)
ZA (1) ZA201300877B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153288B (zh) 2010-07-09 2017-02-15 詹姆斯·特林卡·格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
DE102012102414A1 (de) * 2012-03-21 2013-10-10 Michael Dittgen Pharmazeutische Zusammensetzung für die einmal tägliche Anwendung antidiabetischer Arzneimittel wie Metformin mit Zwei-Puls-Freisetzung
US20150374688A1 (en) * 2013-03-26 2015-12-31 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof.
WO2014170770A1 (en) * 2013-03-28 2014-10-23 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
CN103721261B (zh) * 2014-01-07 2016-01-20 深圳奥萨医药有限公司 含有sglt2抑制剂和b族维生素的药物组合物及其用途
KR101526825B1 (ko) * 2014-12-23 2015-06-08 주식회사 한독 당뇨병 치료용 약제학적 조성물
PH12019502767A1 (en) * 2017-06-08 2020-10-26 Glenmark Pharmaceuticals Ltd Oral pharmaceutical formulations of remogliflozin
WO2019162841A1 (en) * 2018-02-21 2019-08-29 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising remogliflozin for treatment of diabetes mellitus
WO2020037023A1 (en) * 2018-08-14 2020-02-20 Avolynt Method for treating primary sclerosing cholangitis
US20210393662A1 (en) * 2018-10-18 2021-12-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
US11813274B2 (en) 2020-04-22 2023-11-14 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
WO2021212360A1 (en) * 2020-04-22 2021-10-28 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
CN116478895B (zh) * 2023-03-28 2024-03-19 湖南大学 重组鼠伤寒沙门氏菌基因工程菌hcs1、菌剂及其应用
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion
CN120733024A (zh) * 2025-08-15 2025-10-03 可蓝赛生物医药(上海)有限公司 一种缓释型佐剂及其制备方法

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2877269A (en) 1956-04-17 1959-03-10 Wm S Merrell Co Guanyl substituted triphenylethanes, triphenylethylenes and benzalfluorenes
US2868779A (en) 1956-08-28 1959-01-13 Olin Mathieson Process for the purification of streptomycin
DE1039198B (de) 1956-12-12 1958-09-18 Farmaceutici Italia Verfahren zur Herstellung und Gewinnung von Antibiotika
US2928829A (en) 1959-08-31 1960-03-15 Ciba Pharm Prod Inc Alkyleneimino-lower alkyl-guanidines
BE612362A (fr) 1961-01-06 1962-05-02 Parke Davis & Co Composés de la guanidine et procédés pour les préparer.
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
BE757496A (fr) 1969-10-14 1971-03-16 Ono Pharmaceutical Co Nouveaux esters phenyles de l'acide guanidinocaproique et leur production
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (es) 1974-06-07 1981-03-18
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4224316A (en) 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
SE460667B (sv) 1979-09-20 1989-11-06 Nippon Chemiphar Co Cyklohexankarboxylsyraderivat, foerfarande foer framstaellning daerav samt naemnda derivat foer terapeutisk anvaendning
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US4465851A (en) 1981-01-22 1984-08-14 Nippon Chemiphar Co., Ltd. Guanidinocyclohexanecarboxylic acid derivatives
JPS5862152A (ja) 1981-10-08 1983-04-13 Microbial Chem Res Found Ｎ−〔４−（３−アミノプロピル）アミノブチル〕−２−（ω−グアニジノ脂肪酸アミド）−２−ヒドロキシエタンアミドおよびその誘導体ならびにその製造法
US4410512A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4410513A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4544500A (en) 1982-04-14 1985-10-01 Scripps Clinic And Research Foundation Synthetic foot and mouth disease antigen
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
JPS6034190A (ja) 1983-08-05 1985-02-21 Microbial Chem Res Found アルフアメニンの高収率製造法
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
EP0150378B1 (en) 1984-01-23 1990-03-28 Takeda Chemical Industries, Ltd. Cephem compounds and their production
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
JPS6133173A (ja) 1984-07-25 1986-02-17 Torii Yakuhin Kk アミジン化合物
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
JPS62501009A (ja) 1984-12-04 1987-04-23 サンド・アクチエンゲゼルシヤフト メバロノラクトンのインデン同族体及びその誘導体
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
US4732971A (en) 1985-06-03 1988-03-22 Eli Lilly And Company Synthetic vaccines for foot and mouth disease
KR900001212B1 (ko) 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
US4683291A (en) 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
FR2594693B1 (fr) 1986-02-24 1990-01-05 Farah Nabil Nouveaux procedes de preparation a partir d'emulsions seches de formes orales solides a liberation modifiee et retardee de leur principes actifs
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4880778A (en) 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
IT1213495B (it) 1986-09-17 1989-12-20 Sigma Tau Ind Farmaceuti Processo per la preparazione dell'alfa-n-[(ipoxatin-9-il)pentilossicarbonil-]arginina
ES2052595T3 (es) 1986-12-15 1994-07-16 Inst Nat Sante Rech Med Nuevos derivados peptidicos y su aplicacion en especial en terapeutica.
DE3817375C2 (de) 1987-05-22 1997-04-30 Squibb & Sons Inc Phosphorhaltige HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4880777A (en) 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
US4857508A (en) 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
AU639409B2 (en) 1987-12-10 1993-07-29 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
JPH021418A (ja) 1988-03-15 1990-01-05 Toray Ind Inc ３，３’，５，５’―テトラメチルビフェニル―４，４’―ジオールの製造法
JP2873340B2 (ja) 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質ｔａｎ―１０５７，その製造法および用途
ZW6189A1 (en) 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
DE68912775T2 (de) 1988-05-11 1994-06-30 Polygen Holding Corp Polypeptid-verbindungen mit hormonwachstumsbefreiender wirkung.
US4892440A (en) 1988-07-05 1990-01-09 Eveready Flood Control Water backup preventing system and monitoring system therefor
JP2945680B2 (ja) 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5039805A (en) 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5084466A (en) 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en) 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
US5318899A (en) 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
FR2650210B1 (fr) 1989-07-27 1991-10-31 Renault Automation Procede et dispositif de manutention robotise
CA2021952A1 (en) 1989-07-28 1991-01-29 Ruth F. Nutt Fibrinogen receptor antagonists
EP0410537A1 (en) 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
US5061693A (en) 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2021951A1 (en) 1989-07-28 1991-01-29 Ruth F. Nutt Fibrinogen receptor antagonists
EP0410541A1 (en) 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
US4952562A (en) 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
NZ235564A (en) 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
NZ235563A (en) 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
JPH0793363B2 (ja) 1991-09-25 1995-10-09 株式会社半導体エネルギー研究所 半導体集積回路およびその作製方法
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5712396A (en) 1992-10-28 1998-01-27 Magnin; David R. α-phosphonosulfonate squalene synthetase inhibitors
US5883077A (en) 1992-12-15 1999-03-16 Corvas International, Inc. Inhibitors of factor Xa
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
WO1994016693A1 (en) 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5645858A (en) 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
CA2217233A1 (en) * 1995-04-03 1996-10-10 Chugai Seiyaku Kabushiki Kaisha Sucralfate containing pharmaceutical composition
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
BR0016705A (pt) * 1999-12-22 2002-09-24 Pharmacia Corp Composições de liberação dupla de um inibidor de ciclooxigenase-2
ES2248159T3 (es) 1999-12-28 2006-03-16 Ajinomoto Co., Inc. Preparaciones orales para diabetes.
AU2001261434A1 (en) * 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
MXPA03005923A (es) 2000-12-28 2004-01-26 Kissei Pharmaceuticals Co Ltd Derivados de glupopiranosiloxipirazol y su uso en medicinas.
EP1443912B1 (en) 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions having a combination of immediate release and controlled release characteristics
WO2003090723A1 (en) 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
BRPI0313290B1 (pt) 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
DE602004030931D1 (es) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
CN101011364A (zh) * 2005-09-26 2007-08-08 刘凤鸣 二甲双胍罗格列酮的缓释制剂
DE102005048293A1 (de) 2005-10-08 2007-04-12 Sanofi-Aventis Deutschland Gmbh Retardformulierung für Pralnacasan
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
KR100762847B1 (ko) * 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
US8703191B2 (en) 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
MX2009001711A (es) 2006-11-17 2009-05-08 Supernus Pharmaceuticals Inc Formulaciones de liberacion sostenida de topiramato.
CN1985823A (zh) * 2006-11-21 2007-06-27 北京润德康医药技术有限公司 一种含有盐酸二甲双胍罗格列酮的缓释制剂及其制备方法
JP2010523713A (ja) 2007-04-12 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド インスリン分泌を増強するためのラノラジン
CN101254190A (zh) * 2008-04-01 2008-09-03 广州市医药工业研究所 一种复方马来酸罗格列酮二甲双胍控释微球及其制造方法、用途
US8343524B2 (en) 2008-07-31 2013-01-01 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
CN101683340A (zh) * 2008-09-22 2010-03-31 北京利乐生制药科技有限公司 一种复方盐酸二甲双胍罗格列酮的缓释制剂及其制备方法
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
IN2012DN05162A (es) 2009-12-24 2015-10-23 Du Pont
CN103153288B (zh) 2010-07-09 2017-02-15 詹姆斯·特林卡·格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
JP2013114731A (ja) 2011-11-30 2013-06-10 Toshiba Corp 半導体記憶装置
US9200999B2 (en) 2013-09-11 2015-12-01 GM Global Technology Operations LLC Method and system for characterizing color variation of a surface

Also Published As

Publication number Publication date
ES2575860T3 (es) 2016-07-01
JP2013531036A (ja) 2013-08-01
US20130209563A1 (en) 2013-08-15
AU2011276254A1 (en) 2013-02-28
EP2590634A4 (en) 2013-11-13
KR101942590B1 (ko) 2019-01-25
KR20140018832A (ko) 2014-02-13
RU2013105481A (ru) 2014-08-20
CA2804926A1 (en) 2012-01-12
JP2016188240A (ja) 2016-11-04
EP2590634B1 (en) 2016-03-09
CN103153288B (zh) 2017-02-15
CN107080846A (zh) 2017-08-22
WO2012006398A3 (en) 2012-04-05
RU2596787C2 (ru) 2016-09-10
JP6042330B2 (ja) 2016-12-14
MX2013000339A (es) 2015-05-11
WO2012006398A2 (en) 2012-01-12
BR112013000626B1 (pt) 2019-11-26
CA2804926C (en) 2019-01-08
PL2590634T3 (pl) 2016-10-31
AU2011276254B2 (en) 2016-11-03
IL224142B (en) 2018-01-31
RU2016125229A (ru) 2018-12-04
US10940159B2 (en) 2021-03-09
ZA201300877B (en) 2014-04-30
EP2590634A2 (en) 2013-05-15
MY161846A (en) 2017-05-15
BR112013000626A2 (pt) 2016-05-24
CN103153288A (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
MX342120B (es) Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin.
GB0724478D0 (en) Pharmaceutical compositions
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
MY148637A (en) Anti-glypican-3 antibody having improved kinetics in plasma
MX2010002675A (es) Profarmacos para analogos de hormonas tiroideas.
MX2010014057A (es) Compuestos de piridina.
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
PT2252284E (pt) COMPOSIÇÕES FARMACjUTICAS DE ENTACAPONE, LEVODOPA E CARBIDOPA COM BIODISPONIBILIDADE MELHORADA
WO2012010977A8 (en) Single daily dosage form for prevention and treatment of metabolic syndrome
MY160249A (en) Fatty acid fumarate derivatives and their uses
MY168763A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
IN2014DN01619A (es)
MY165041A (en) Composition for improving brain function and method for improving brain function
PH12014501408A1 (en) Immediate release multi unit pellet system
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
GB0606212D0 (en) Pharmaceutical compositions
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
WO2014006636A3 (en) Stable compositions of fesoterodine
EA201390844A1 (ru) Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
WO2013078396A3 (en) Radiation-sterilized biodegradable drug delivery compositions
WO2012064130A3 (ko) 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
MX2013003288A (es) Elaboracion de tabletas a partir de una mezcla en polvo con aplicacion de energia.
MX2009002985A (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (tsh).
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.
WO2012150784A3 (ko) 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
FG Grant or registration